IS6264A - Arýlmetýl-karbónýlamínó-þíósól afleiður og notkunþeirra sem miðla gegn æxlum - Google Patents

Arýlmetýl-karbónýlamínó-þíósól afleiður og notkunþeirra sem miðla gegn æxlum

Info

Publication number
IS6264A
IS6264A IS6264A IS6264A IS6264A IS 6264 A IS6264 A IS 6264A IS 6264 A IS6264 A IS 6264A IS 6264 A IS6264 A IS 6264A IS 6264 A IS6264 A IS 6264A
Authority
IS
Iceland
Prior art keywords
thiosol
arylmethyl
carbonylamino
derivatives
tumor agents
Prior art date
Application number
IS6264A
Other languages
English (en)
Other versions
IS2594B (is
Inventor
Pevarello Paolo
Amici Raffaella
Villa Manuela
Salom Barbara
Vulpetti Anna
Varasi Mario
Original Assignee
Pharmacia Italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia S.P.A. filed Critical Pharmacia Italia S.P.A.
Publication of IS6264A publication Critical patent/IS6264A/is
Publication of IS2594B publication Critical patent/IS2594B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IS6264A 1999-08-12 2002-02-11 Arýlmetýl-kabónýlamínó-þíasólafleiður og notkun þeirra sem æxlishemjandi efni IS2594B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/372,832 US6114365A (en) 1999-08-12 1999-08-12 Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
PCT/IB2000/001423 WO2001014353A1 (en) 1999-08-12 2000-08-11 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents

Publications (2)

Publication Number Publication Date
IS6264A true IS6264A (is) 2002-02-11
IS2594B IS2594B (is) 2010-03-15

Family

ID=23469806

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6264A IS2594B (is) 1999-08-12 2002-02-11 Arýlmetýl-kabónýlamínó-þíasólafleiður og notkun þeirra sem æxlishemjandi efni

Country Status (36)

Country Link
US (3) US6114365A (is)
EP (1) EP1204649B1 (is)
JP (1) JP4864260B2 (is)
KR (2) KR100773709B1 (is)
CN (1) CN100410245C (is)
AP (1) AP1853A (is)
AT (1) ATE375987T1 (is)
AU (1) AU782882B2 (is)
BG (1) BG65484B1 (is)
BR (1) BR0013281A (is)
CA (1) CA2381097C (is)
CY (1) CY1107108T1 (is)
CZ (1) CZ303138B6 (is)
DE (1) DE60036803T2 (is)
DK (1) DK1204649T3 (is)
EA (1) EA005375B1 (is)
EE (1) EE04939B1 (is)
ES (1) ES2295056T3 (is)
GE (1) GEP20053475B (is)
HK (1) HK1054233B (is)
HR (1) HRP20020127B1 (is)
HU (1) HUP0202492A3 (is)
IL (2) IL147924A0 (is)
IS (1) IS2594B (is)
MA (1) MA25433A1 (is)
MX (1) MXPA02001508A (is)
NO (1) NO323576B1 (is)
NZ (1) NZ517236A (is)
OA (1) OA12047A (is)
PT (1) PT1204649E (is)
RS (1) RS50300B (is)
SI (1) SI1204649T1 (is)
SK (1) SK287373B6 (is)
UA (1) UA72538C2 (is)
WO (1) WO2001014353A1 (is)
ZA (1) ZA200201117B (is)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150921A1 (en) * 1996-02-09 2002-10-17 Francis Barany Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US6407103B2 (en) 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
EP2308833A3 (en) 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20040048844A1 (en) * 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
US20040019046A1 (en) * 2000-11-27 2004-01-29 Paolo Pevarello Phenylacetamido-pyrazole derivatives and their use as antitumor agents
WO2002044174A2 (en) * 2000-12-01 2002-06-06 Bristol-Myers Squibb Pharma Company 3-(2,4-dimethylthiazol-5-yl) indeno[1,2-c]pyrazol-4-one derivatives as cdk inhibitors
JP2004538247A (ja) 2000-12-08 2004-12-24 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー セミカルバジド及びサイクリン依存キナーゼ阻害剤
JP4405726B2 (ja) 2000-12-21 2010-01-27 ブリストル−マイヤーズ スクイブ カンパニー Ｔｅｃファミリーチロシンキナーゼのチアゾリルインヒビター
ES2254611T3 (es) * 2001-05-11 2006-06-16 Pfizer Products Inc. Derivados de tiazol.
EP1724270A3 (en) 2001-07-19 2007-01-03 Pfizer Italia S.r.l. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
CN1286835C (zh) * 2001-07-19 2006-11-29 法玛西雅意大利公司 苯乙酰氨基噻唑衍生物、它们的制备方法和它们作为抗肿瘤剂的用途
EP1436286B1 (en) * 2001-09-27 2009-08-19 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
RU2374236C2 (ru) * 2001-12-21 2009-11-27 Ново Нордиск А/С Амидные производные в качестве активаторов gk
BR0312023A (pt) * 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
BRPI0407456A (pt) * 2003-02-12 2006-01-31 Pfizer Derivados antiproliferativos de 2-(sulfo-fenil)-aminotiazole e composições farmacêuticas, e métodos para o seu uso
CA2516234A1 (en) * 2003-02-21 2004-09-02 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
CA2520957C (en) * 2003-03-31 2013-08-06 Sucampo Ag Method for treating vascular hyperpermeable disease
WO2005014591A1 (en) * 2003-07-15 2005-02-17 L'oreal 2-acylamino or 2-sulfonylamino-1, 3-thiazoles as couplers for the oxidation dyeing of keratin fibres
FR2857664B1 (fr) * 2003-07-15 2007-12-14 Oreal Nouveaux derives thiazoles et utilisation de ces derives pour la teinture des fibres keratiniques
US7351727B2 (en) * 2003-09-02 2008-04-01 Bristol-Myers Squibb Company Inhibitors of 15-lipoxygenase
US20050074424A1 (en) * 2003-10-03 2005-04-07 Lev Salnikov Using polyion polymers with glucose infusion for a cancer selective chemotherapy compound and method
US20070196395A1 (en) * 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
MXPA06007667A (es) * 2004-01-06 2006-09-01 Novo Nordisk As Heteroaril-ureas y su uso como activadores de glucocinasa.
EP2027853A3 (en) 2004-06-18 2011-01-05 Agennix USA Inc. Kinase inhibitors for treating cancers
EP1621539A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
BRPI0515012A (pt) * 2004-08-13 2008-07-01 Genentech Inc substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
EP2096107A1 (en) 2004-12-23 2009-09-02 GPC Biotech AG Derivatives of squaric acid with anti-proliferative activity
CN101208089A (zh) * 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
EP1904438B1 (en) * 2005-07-08 2012-02-29 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
US7884210B2 (en) 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008084043A1 (en) * 2007-01-09 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
CA2675111C (en) * 2007-01-11 2016-04-05 Novo Nordisk A\S Urea glucokinase activators
CN103342701B (zh) * 2007-02-13 2016-09-21 Ab科学有限公司 作为激酶抑制剂的2-氨基噻唑化合物多晶型及其制备方法
US8450348B2 (en) * 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
TWI437986B (zh) * 2008-01-31 2014-05-21 R Tech Ueno Ltd 噻唑衍生物及使用該衍生物作為ｖａｐ－１抑制劑之用途
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
BRPI0920927A2 (pt) 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
TWI504598B (zh) * 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
DE102009043260A1 (de) * 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
HU0900798D0 (en) 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
WO2012092471A2 (en) * 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
CN103387551B (zh) * 2012-05-11 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 噻唑类化合物及其用途
MX355354B (es) 2012-08-23 2018-04-17 Virostatics Srl Derivados aminopirimidinicos 4,6-disustituidos novedosos.
ES2928408T3 (es) 2016-04-11 2022-11-17 Genfit Métodos para el tratamiento de enfermedades fibróticas
AU2018380132B2 (en) 2017-12-06 2023-11-09 Lin Bioscience, Inc. Tubulin inhibitors
AU2019215799B2 (en) * 2018-02-01 2022-04-14 The University Of Sydney Anti-cancer compounds
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
EP3712127A1 (en) 2019-03-22 2020-09-23 Deutsches Krebsforschungszentrum Novel inhibitors of histone deacetylase 10
EP3941900A1 (en) 2019-03-22 2022-01-26 Deutsches Krebsforschungszentrum Novel inhibitors of histone deacetylase 10
JPWO2021162054A1 (is) * 2020-02-10 2021-08-19
CN115322208B (zh) * 2021-05-10 2023-04-11 中国药科大学 2-氨基噻唑类衍生物及其制备方法和医药用途
WO2023182780A1 (ko) * 2022-03-22 2023-09-28 오토텔릭바이오 주식회사 티아졸 유도체 화합물 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125062C (is) * 1960-04-20
TW513418B (en) * 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
JPH1095777A (ja) * 1996-07-31 1998-04-14 Otsuka Pharmaceut Co Ltd チアゾール誘導体
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
EP1056732B1 (en) * 1997-10-27 2006-01-11 Agouron Pharmaceuticals, Inc. 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
DE69923681T2 (de) * 1998-06-18 2006-01-12 Bristol-Myers Squibb Co. Kohlenstoff substituierte aminothiazole als inhibitoren von cyclin-abhängigen kinasen
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
EP2308833A3 (en) * 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6992081B2 (en) * 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
SE0102440D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compound
DE60221627D1 (de) * 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
KR20120030601A (ko) * 2003-01-27 2012-03-28 아스텔라스세이야쿠 가부시키가이샤 티아졸 유도체 및 ｖａｐ-1 저해제로서의 용도

Also Published As

Publication number Publication date
US6114365A (en) 2000-09-05
JP4864260B2 (ja) 2012-02-01
AP2002002441A0 (en) 2002-03-31
GEP20053475B (en) 2005-03-25
HRP20020127A2 (en) 2003-04-30
OA12047A (en) 2006-05-02
YU9702A (sh) 2004-11-25
EP1204649B1 (en) 2007-10-17
WO2001014353A1 (en) 2001-03-01
US20050004120A1 (en) 2005-01-06
KR20070074003A (ko) 2007-07-10
CZ303138B6 (cs) 2012-04-25
EE200200064A (et) 2003-04-15
DE60036803T2 (de) 2008-07-24
HRP20020127B1 (en) 2010-08-31
EA005375B1 (ru) 2005-02-24
PT1204649E (pt) 2008-01-10
MA25433A1 (fr) 2002-04-01
PL353588A1 (en) 2003-12-01
CA2381097C (en) 2009-06-16
SK287373B6 (sk) 2010-08-09
ZA200201117B (en) 2003-04-30
HK1054233A1 (en) 2003-11-21
HK1054233B (zh) 2009-05-29
CZ2002486A3 (cs) 2002-11-13
AU782882B2 (en) 2005-09-08
US6784198B1 (en) 2004-08-31
HUP0202492A3 (en) 2004-12-28
KR100827563B1 (ko) 2008-05-07
MXPA02001508A (es) 2003-07-21
IS2594B (is) 2010-03-15
DK1204649T3 (da) 2007-12-03
ATE375987T1 (de) 2007-11-15
RS50300B (sr) 2009-09-08
KR20020060159A (ko) 2002-07-16
NO20020683D0 (no) 2002-02-11
IL147924A0 (en) 2002-08-14
HUP0202492A2 (hu) 2002-11-28
BG65484B1 (bg) 2008-09-30
EP1204649A1 (en) 2002-05-15
EA200200247A1 (ru) 2002-08-29
DE60036803D1 (de) 2007-11-29
NO323576B1 (no) 2007-06-11
NZ517236A (en) 2004-11-26
CN1425009A (zh) 2003-06-18
CY1107108T1 (el) 2012-10-24
IL147924A (en) 2008-03-20
CN100410245C (zh) 2008-08-13
NO20020683L (no) 2002-04-10
JP2003507461A (ja) 2003-02-25
EE04939B1 (et) 2007-12-17
KR100773709B1 (ko) 2007-11-09
BG106481A (en) 2002-09-30
BR0013281A (pt) 2002-06-18
UA72538C2 (en) 2005-03-15
AU7440000A (en) 2001-03-19
SK1802002A3 (en) 2003-05-02
SI1204649T1 (sl) 2008-02-29
CA2381097A1 (en) 2001-03-01
AP1853A (en) 2008-05-29
ES2295056T3 (es) 2008-04-16

Similar Documents

Publication Publication Date Title
IS6264A (is) Arýlmetýl-karbónýlamínó-þíósól afleiður og notkunþeirra sem miðla gegn æxlum
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
IS6411A (is) Kaspasa tálmar og notkun þeirra
MA26774A1 (fr) Derives de pyridinyl et de phenyl
NO991151D0 (no) Forbindelse og anvendelse derav
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
ATE263748T1 (de) Admantan-derivate
IS6594A (is) 2-asýl indól afleiður og notkun þeirra sem miðla gegn æxlum
ATE293104T1 (de) Thiazolylamid-derivate
DE69903143D1 (de) Chromanon und thiochromanon derivate
ATE257148T1 (de) Propargyletherderivate
HU0001396D0 (en) 3-amino-3-arylpropan-1-al derivatives and their use
IS5942A (is) 3,3-bíarýlpíperidín og 2,2-bíarýlmorfólín afleiður
NO986174D0 (no) Triazinderivater og anvendelse derav
ATE273272T1 (de) Mevinolinderivate
IS2773B (is) Amínókínólínafleiður og notkun þeirra sem adenósín A3-bindlar
ATE254598T1 (de) 4-hydroxybiphenylhydrazid-derivate
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
GB0023323D0 (en) Arylhydantoin derivatives and uses thereof
FI19992112A (fi) Synkronointimenetelmä ja -järjestely
NO20005031D0 (no) Kinolin-4-yl-derivater II
DK1088818T3 (da) Quinolin-4-yl-derivater
DE60015471D1 (de) Chinolin-4-yl-derivate
ATE317386T1 (de) Dihydroindol- und tetrahydrochinolinderivate